IMUX Company Profile and Key Details
Immunic, Inc.
IMUX Stock Price Chart
Stock Price Today
Immunic, Inc. (IMUX) stock surged +1.05%, trading at $0.96 on NASDAQ, up from the previous close of $0.95. The stock opened at $0.99, fluctuating between $0.95 and $1.00 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Company Information
| Employees | 85 |
| Beta | 1.88 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Immunic, Inc. (NASDAQ: IMUX) stock price is $0.96 in the last trading session. During the trading session, IMUX stock reached the peak price of $1.00 while $0.95 was the lowest point it dropped to. The percentage change in IMUX stock occurred in the recent session was 1.05% while the dollar amount for the price change in IMUX stock was $0.01.
The NASDAQ listed IMUX is part of Biotechnology industry that operates in the broader Healthcare sector. Immunic, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A
Executive Chairman
Mr. Glenn Whaley CPA
Chief Financial Officer
Mr. Inderpal Singh
Gen. Counsel
Dr. Hella Kohlhof
Chief Scientific Officer
Mr. Patrick Walsh
Chief Bus. Officer
Dr. Daniel Vitt
Chief Executive Officer, Pres & Director
Jessica Breu
Head of Investor Relations & Communications
Dr. Andreas Muehler M.D., Ph.D.
Chief Medical Officer
Dr. Daniel Vitt Ph.D.
Chief Executive Officer, Pres & Director
Dr. Duane D. Nash J.D., M.B.A, M.B.A., M.D.
Executive Chairman
IMUX's closing price is 2.92% higher than its 52-week low of $0.92 where as its distance from 52-week high of $2.11 is -54.98%.
Number of IMUX employees currently stands at 85.
Official Website of IMUX is: https://www.immunic-therapeutics.com
IMUX could be contacted at phone 332 255 9818 and can also be accessed through its website. IMUX operates from 1200 Avenue of the Americas, New York, NY 10036, United States.
IMUX stock volume for the day was 666.38K shares. The average number of IMUX shares traded daily for last 3 months was 988.73K.
The market value of IMUX currently stands at $86.48M with its latest stock price at $0.96 and 90.08M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com